Special Issue

Advancing Cancer Immunotherapy: Unleashing the Potential of the Immunological Synapse

Message from the Guest Editor

The immunological synapse, is a specialized cell–cell junction formed between immune cells. This Special Issue will primarily highlight the latest research advancements concerning the immunological synapse, including but not limited to:

- Structure and Formation—Investigating the molecular architecture, dynamic formation, and key proteins involved in immunological synapses.
- Signaling and Function—Examining signaling pathways, impact on immune-cell activation and proliferation, and cross-talk between immune cells and antigen-presenting cells in synapses.
- Role in Cancer Immunotherapy—Exploring synapse dysfunction in cancer immune evasion, role in immunotherapies' efficacy, and developing strategies for improved treatment outcomes.
- Microenvironment and Interactions—Understanding how the tumor microenvironment affects synapse formation; investigating interactions among immune, tumor, and stromal cells; and their influence on tumor immune response.
- Technological Advances—Developing real-time imaging techniques, computational modeling for synapse dynamics, and engineering synthetic synapses for targeted therapies.

Guest Editor

Dr. Zhizhan Gu

American Type Culture Collection (ATCC), Gaithersburg, MD 20877, USA

Deadline for manuscript submissions

closed (30 November 2024)

Biomedicines

mdpi.com/journal/
biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).